The maximum dose test for guinea pig sensitization reaction

Guinea Pig Maximization Test (GPMT) for Skin Sensitization – Dose‑Finding and Potency Classification for Chemicals, Cosmetics and Medical Devices

As an ISO/IEC 17025 accredited contract research laboratory, we offer the Guinea Pig Maximization Test (GPMT) – a validated and internationally accepted assay for assessing the contact sensitization potential of chemical substances, formulations, and medical device extracts. The GPMT, developed by Magnusson and Kligman, is a rigorous in vivo method that identifies the maximum non‑irritating induction dose and the threshold for elicitation, thereby providing a reliable hazard classification (weak, moderate, strong, or extreme sensitizer). This test is widely required for regulatory submissions under REACH, CLP, Biocidal Products Regulation (BPR), Cosmetics Regulation (EC) No 1223/2009, and ISO 10993‑10 for medical devices. All procedures are conducted in strict compliance with Directive 2010/63/EU, the Bulgarian Animal Welfare Act, and OECD Test Guideline 406. Our reports are recognised by the Bulgarian Food Safety Agency (BFSA), the European Chemicals Agency (ECHA), and Bulgarian and EU regulatory authorities for product registration, hazard communication, and classification.

Test Material and Product Types We Evaluate

Our GPMT laboratory handles a wide variety of substances and product extracts. Typical test articles include:

Industrial chemicals and intermediates – monomers, solvents, preservatives, cross‑linkers, and processing aids
Cosmetic ingredients and formulations – fragrances, preservatives, emulsifiers, and active ingredients
Medical device extracts (ISO 10993‑10) – from polymers, metals, ceramics, and coated surfaces
Biocidal active substances and formulated products – disinfectants, insect repellents, and surface sanitisers
Agricultural chemicals – pesticides, herbicides, fungicides, and adjuvants
Food contact materials and additives – packaging components and food‑grade chemicals
Drug substances and excipients – for topical and transdermal pharmaceutical products

Test System and Animal Housing

We use healthy, young adult (6‑12 weeks old) female or male Dunkin‑Hartley guinea pigs, a strain that has been extensively validated for sensitisation studies. The main husbandry and welfare parameters include:

Housing – animals are housed in pairs or groups in standard stainless‑steel cages with solid floors and appropriate enrichment (e.g., hiding tubes, nesting material)
Environmental conditions – temperature 20‑24 °C, relative humidity 40‑70 %, 12‑hour light/dark cycles
Diet and water – ad libitum access to standard guinea pig pelleted diet and reverse‑osmosis water from automatic watering systems
Acclimation – a minimum 5‑day acclimatisation period to the laboratory environment before any procedure
Health monitoring – daily clinical checks for signs of distress, weight loss, or disease; any animal showing > 15 % weight loss or severe morbidity is removed and humanely euthanised

Experimental Design – Dose‑Finding and Maximization Protocol (OECD TG 406)

The GPMT follows a three‑stage design to induce maximum sensitisation and assess the elicited response. The stages are:

Stage 1 – Dose‑finding (intradermal induction – maximum non‑irritating concentration) – we determine the highest concentration of the test substance that does not cause severe irritation or necrosis when injected intradermally in a small pilot group of guinea pigs. Typically, three concentrations are tested: 1 %, 5 %, and 10 % (or lower for irritant substances). The maximum non‑irritating concentration (MNC) is selected for the main induction phase.
Stage 2 – Induction (intradermal injection with adjuvant) – a group of 10‑20 guinea pigs receives three sets of intradermal injections in the shaved dorsal region (six injection sites per animal) on day 1. Each set consists of: (a) the test substance at the MNC (in an appropriate vehicle), (b) the vehicle only, and (c) the test substance in Freund’s Complete Adjuvant (FCA) to enhance the immune response. The FCA emulsion is carefully prepared to ensure proper dispersion of the test article.
Stage 3 – Topical challenge – 14‑21 days after the intradermal induction, the same animals are subjected to a topical challenge: a patch containing the test substance at a non‑irritating concentration (determined from a separate dose‑finding patch test) is applied to the shaved skin (left flank) for 24 hours. A control patch with the vehicle alone is applied to the contralateral (right) flank to distinguish between irritant and sensitisation reactions.
Positive and negative controls – a parallel group receives a known sensitizer (e.g., 2,4‑dinitrochlorobenzene – DNCB) as a positive control to validate the test system; a separate group receives only the vehicle to establish the background response.

Dose‑Finding for Topical Challenge – Non‑irritating Concentration Determination

Before the challenge phase, we perform a preliminary patch test to identify the highest concentration of the test substance that does not cause primary irritation. The procedure includes:

Patch application – to a fresh batch of guinea pigs (or to the same animals before induction), we apply a patch with increasing concentrations of the test substance (e.g., 0.5 %, 1 %, 2 %, 5 %, 10 %) to the shaved skin for 24 hours
Scoring – at 24 and 48 hours after patch removal, we evaluate erythema and oedema using a 0‑4 scale (0 = none, 1 = very slight erythema, 2 = well‑defined erythema, 3 = moderate to severe erythema, 4 = severe erythema with oedema). The non‑irritating concentration is defined as the highest concentration that produces a score ≤ 1 in all animals
Selection – the concentration selected for the challenge is typically the highest non‑irritating concentration, or if no non‑irritating concentration is found, we use the lowest irritant concentration and adjust the patch duration (e.g., 3‑6 hours instead of 24)

Elicitation and Scoring – Assessment of Sensitisation Response

The main sensitisation assessment is based on the skin reaction observed 24 and 48 hours after challenge patch removal. The scoring system is as follows:

Erythema and eschar formation – 0 = no erythema, 1 = very slight erythema (barely perceptible), 2 = well‑defined erythema, 3 = moderate to severe erythema, 4 = severe erythema (beet‑red) to slight eschar formation (injuries in depth)
Oedema formation – 0 = no oedema, 1 = very slight oedema (barely perceptible), 2 = slight oedema (edges of area well defined by definite raising), 3 = moderate oedema (raised approximately 1 mm), 4 = severe oedema (raised more than 1 mm and extending beyond the exposure area)
Total score – the sum of erythema and oedema scores (maximum 8). A reaction is considered positive if the total score ≥ 1 (i.e., any visible erythema or oedema) at any observation point
Intensity classification – based on the percentage of positive animals, the sensitisation potential is classified as: weak (0‑20 %), moderate (20‑40 %), strong (40‑70 %), or extreme (≥ 70 %)

Histopathological Confirmation (Optional)

In cases of doubtful reactions or to confirm the nature of the response (irritant vs. allergic), we perform skin biopsies from the challenge sites. The biopsied tissue is:

Fixed – in 10 % neutral buffered formalin, embedded in paraffin, sectioned (4‑6 µm), and stained with Haematoxylin & Eosin (H&E)
Examined – under light microscopy for the presence of perivascular mononuclear cell infiltrates, epidermal spongiosis, and oedema, which are characteristic of allergic contact dermatitis, as opposed to the predominantly neutrophilic infiltrate seen in irritant reactions
Scored – the histopathological score (0‑4) is based on the intensity of the inflammatory infiltrate and the extent of epidermal damage

Statistical Analysis and Interpretation

We provide a comprehensive statistical evaluation of the results to support your regulatory dossier. The analysis includes:

Response rate – the proportion of positive responders in each group; compared to the negative control using Fisher’s exact test
Severity index – the mean total score per group; compared using the Mann‑Whitney U test or one‑way ANOVA (if normally distributed)
Classification – based on the percentage of positive animals and the severity of reactions, we assign a hazard category (e.g., “Skin Sensitizer Category 1A” for strong/extreme, “Category 1B” for moderate/weak) according to CLP (GHS) criteria
No observed effect level (NOEL) – if applicable, the maximum concentration that produces no positive reactions is reported as the NOEL for sensitisation

Quality Control and Test Validity Criteria

To ensure the test is valid, we verify the following criteria:

Positive control response – the group receiving the positive control (e.g., 2,4‑dinitrochlorobenzene) must show a ≥ 80 % sensitisation rate; otherwise, the test system is considered compromised
Negative control response – the vehicle‑only group must show ≤ 10 % positive reactions (i.e., no more than 1‑2 animals with erythema, typically due to mechanical irritation)
No severe systemic toxicity – all animals must survive the induction and challenge phases without significant weight loss (> 15 %) or moribund condition; such animals are excluded from analysis and the study is repeated if more than 10 % are affected
Proper induction – the intradermal injection must produce a visible wheal (indicating proper intradermal delivery) in at least 90 % of the injection sites

Ethical Compliance and Animal Welfare

All GPMT studies are conducted in accordance with Directive 2010/63/EU, the Bulgarian Animal Welfare Act, and the OECD TG 406 guidelines. Our institution’s ethics committee approves all protocols before initiation. We adhere to the 3Rs principles:

Replacement – we use non‑animal alternatives (e.g., Local Lymph Node Assay – LLNA, or in vitro skin sensitisation assays like the KeratinoSens™ assay) for substances that are negative in early screening; we reserve the GPMT for materials that require full classification or are not suitable for LLNA (e.g., insoluble substances or coloured compounds)
Reduction – we use the minimum number of animals per group required to achieve statistical significance (typically 10‑20 per group for the test, and 5 for controls), and we use historical control data to reduce the need for concurrent positive controls in routine screens
Refinement – we use light sedation (isoflurane) during intradermal and patch applications to minimise stress, and we provide post‑procedural analgesia (buprenorphine) if any irritation is observed; we also use non‑invasive adhesive patches that cause minimal discomfort

Report Acceptance & Compliance with Bulgarian and EU Regulations

All GPMT studies are performed under our ISO/IEC 17025 accreditation and in compliance with Good Laboratory Practice (GLP) principles. Our final study reports provide a complete description of the test substance, vehicle, concentrations used, and the rationale for dose selection; a detailed account of the induction and challenge procedures; individual animal reaction scores (with photographic documentation of challenge sites); statistical summaries (response rates, severity indices, classification); histopathological findings (if performed); and a clear conclusion on the sensitisation potential, including the CLP/GHS classification and the assigned hazard statement (e.g., “May cause an allergic skin reaction” – H317). These reports are accepted by the Bulgarian Food Safety Agency (BFSA), the European Chemicals Agency (ECHA), and other regulatory bodies for REACH registration, CLP notification, cosmetic product safety assessments, and medical device biological evaluations (ISO 10993‑10). Bilingual (Bulgarian/English) versions are available to facilitate submission to national and European authorities.